

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-6. (Canceled)

Claim 7. (Currently Amended) A method of modulating blood vessel formation in a subject in need, comprising locally administering a functional Tissue Factor ~~tissue factor~~ in a therapeutically effective amount to said subject in need, wherein said Tissue Factor ~~tissue factor~~ or a fragment thereof is administered in the form of an expressible nucleic acid, and wherein the administration of the functional Tissue Factor ~~tissue factor~~ modulates blood vessel formation in non-malignant tissue; wherein the modulating is an activation of blood vessel formation.

Claim 8. (Previously Presented) The method of claim 7, wherein said nucleic acid is expressed transiently.

Claim 9. (Previously Presented) The method of claim 7, wherein said nucleic acid is a DNA.

Claim 10. (Previously Presented) The method of claim 7, wherein said nucleic acid is controlled by a constitutive or an inducible promoter.

Claim 11. (Previously Presented) The method of claim 7, wherein said nucleic acid is present in a Sindbis virus replicon vector.

Claim 12. (Previously Presented) The method of claim 7, wherein said nucleic acid is controlled by a CMV or SV40 promoter.

Claim 13. (Currently Amended) The method of claim 20 or 21, wherein said Tissue Factor ~~tissue factor~~ is present in a liposome or on a carrier.

Claim 14. (Currently Amended) The method of claim 17, wherein said Tissue Factor ~~tissue factor~~ is present in combination with further factors promoting the formation of blood vessels.

Claim 15. (Previously Presented) The method of claim 14, wherein said further factors are present as expressible nucleic acids or functional proteins.

Claim 16. (Previously Presented) The method of claim 15, wherein at least one further factor is present and said further factor is VEGF.

Claim 17. (Currently Amended) The method of claim 20 or 21, wherein said Tissue Factor tissue factor is present in a pharmaceutical composition.

Claim 18. (Withdrawn) A pharmaceutical composition for modulation of blood vessel formation, comprising tissue factor or a fragment thereof and a pharmaceutically acceptable carrier.

Claim 19. (Withdrawn) A pharmaceutical composition for activation of blood vessel formation, comprising tissue factor or a fragment thereof and a pharmaceutically acceptable carrier.

Claim 20. (Currently Amended) A method for modulating blood vessel formation in a subject in need, comprising inducing local expression of a Tissue Factor tissue factor nucleic acid in said subject in need thereof; wherein the modulating is an activation of blood vessel formation in non-malignant tissue.

Claim 21. (Currently Amended) A method for enhancing wound healing in a subject in need, comprising inducing local expression of a Tissue Factor tissue factor nucleic acid in said subject in need.

Claim 22. (Canceled)

Claim 23. (Previously Presented) The method of claim 20, wherein said nucleic acid is expressed transiently.

Claim 24. (Previously Presented) The method of claim 20, wherein said nucleic acid is a DNA.

Claim 25. (Previously Presented) The method of claim 20, wherein said nucleic acid is controlled by a constitutive or an inducible promoter.

Claim 26. (Previously Presented) The method of claim 20, wherein said nucleic acid is present in a Sindbis virus replicon vector.

Claim 27. (Previously Presented) The method of claim 20, wherein said nucleic acid is controlled by a CMV or SV40 promoter.

Claim 28. (Original) The method of claim 13, wherein said carrier is a gold particle.

Claim 29. (Canceled)

Claim 30. (Previously Presented) The method of claim 7, wherein the said subject in need is afflicted with diabetes mellitus, vasculitis, arterial conclusive disease, chronic venous and infected ulcer, innervation impairment, decubital gangrene or weak sutures after a surgery.

Claim 31. (Previously Presented) The method of claim 7, wherein said subject in need is afflicted with arteriosclerosis, Crohn's disease, ulcerative colitis, diabetic retinopathy, or deep venous thrombosis of the legs ulcus cruris.

Claim 32. (Previously Presented) The method of claim 7, wherein the blood vessel formation is activated for the replacement of impaired blood vessels.

Claim 33. (Previously Presented) The method of claim 20, wherein the said subject in need is afflicted with diabetes mellitus, vasculitis, arterial conclusive disease, chronic venous and infected ulcer, innervation impairment, decubital gangrene or weak sutures after a surgery.

Claim 34. (Previously Presented) The method of claim 20, wherein said subject in need is afflicted with arteriosclerosis, Crohn's disease, ulcerative colitis, diabetic retinopathy, or deep venous thrombosis of the legs ulcus cruris.

Attorney's Docket No. 012627-028

Application No. 09/423,712

Page 7

Claim 35. (Previously Presented) The method of claim 20, wherein the blood vessel formation is activated for the replacement of impaired blood vessels.